Civica to Manufacture and Distribute Affordable Insulin

Through a transformative collaboration between Civica and dedicated partners representing nearly every corner of the diabetes ecosystem, Americans with diabetes will have access to more affordable insulins. This transparent, cost-plus model will drastically reduce out-of-pocket costs for insulin.

“Diabetes is arguably America’s most expensive chronic condition, and it is heartbreaking that millions of people are rationing their care and putting their lives at risk because they can no longer afford insulin. Through mission-driven partnerships, we are choosing to create a new market reality where no one is forced to ration essential diabetes medications.”

Insulin Has Been Around for 100 Years, So Why Is It Still So Expensive?

“Our objective is to generate a societal return, improving affordability and alleviating human suffering while demonstrating that market solutions exist that can help moderate the effects of capitalism unrestrained by notions of right and wrong—models that put the needs of the patient first and always.”

A Radical Treatment for Insulin Pricing

“If Civica does deliver on its plan, it will disrupt the status quo for an important set of drugs and establish a path for reducing prices for other biologic medications whose market exclusivity periods have passed.”

Civica Announces Leadership Transition

Effective June 1, Ned McCoy, formerly Civica’s Chief Operating Officer, succeeds Martin VanTrieste as Civica’s President and Chief Executive Officer. Martin remains an advisor to the Company and continues serving on Civica’s Board of Directors. As part of this transition, Ned also joins the Civica Board of Directors.

“I look forward to continuing to work with our talented team and furthering our culture of innovation, excellence and dedication to improving patient lives with a new model for generic hospital and prescription medicines.”

Profil Selected as Clinical Trial Partner for Affordable Insulin Initiative

Civica chose Profil as clinical trial partner to support the development of its affordable insulin biosimilars. Profil is the leading clinical research organization for studies related to diabetes and obesity.

Civica Joins the End Drug Shortages Alliance

Shortages of generic drugs critical to the lifesaving work of hospitals in the U.S. have become far too commonplace. Working to solve this issue, Civica has joined the End Drug Shortages Alliance, a new coalition of diverse stakeholders to address drug shortages in the United States.

Navitus Health Solutions Joins CivicaScript™

Navitus Health Solutions joins CivicaScript™ as a founding member. An industry-disrupting pharmacy benefit manager (PBM), Navitus is committed to bringing humanity to pharmacy benefits management through greater transparency and affordability.

“20 to Watch” from Fierce Healthcare

Civica President and CEO Ned McCoy is one of 20 executives recognized by Fierce Healthcare as leaders who are on the front line of the healthcare industry evolution.

CivicaScript™ Announces Launch of its First Product, Creating Significant Patient Savings

CivicaScript™ launches its first product: abiraterone acetate 250 mg tablets. Abiraterone is used together with steroid medication (prednisone) to treat prostate cancer that has spread to other parts of the body. The cost? As much as $3,000 per month less than the average cost for someone with Medicare Part D, the type of insurance people with prostate cancer are most likely to have.

Civica to Expand in Greater Richmond-Petersburg Region, Investing in New Testing Facility

Civica announces the construction of a 55,000 square foot facility to support the company’s Petersburg manufacturing operation through quality testing and development of new products. The project will create 51 new jobs.

“With this investment, Civica is building on its long-term commitment to patients – and to Virginia. This lab will support a skilled and highly trained workforce who will ensure Civica’s affordable insulin as well as other essential medicines meet the highest standards.”

Insulin Spending Caps Won’t Work. Here’s a Better Idea

With fairer rules in place, competitors should be able to force down the cost of insulin overall, to the benefit of consumers and taxpayers alike. Wherever possible, the goal should be removing impediments… and making it harder for the major manufacturers to maintain the status quo.

Insulin Costs Increased 600% Over the Last 20 Years. States Aim to Curb the Price

As leading manufacturers have increased prices of insulin by more than 600% over the last 20 years, many diabetes patients ration this lifesaving drug. So who’s helping?

Here’s the road to the future home of affordable insulin and essential sterile injectable medicines hospitals rely on every day.

The new address of our Civica Petersburg manufacturing facility is “One Civica Way”